A Study to Evaluate Solriktug in Adult Participants With Asthma
Phase 2
124
about 1.8 years
18–75
74 sites in AL, AZ, CA +23
What this study is about
Researchers are testing solriktug, a biological treatment, in adult participants with asthma. The trial will evaluate the safety and tolerability of solriktug compared to placebo over 12 weeks. Participants will receive either solriktug or placebo via subcutaneous injection at it site.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive NSI-8226
- 2.Receive Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: To assess the safety and tolerability of multiple doses of solrikitug
Respiratory